DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cetuximab
Cetuximab
I4X-JE-JFCM an Open-Label, Multicenter, Phase 1B/2 Study To
Erbitux® (Cetuximab)
Monoclonal Antibodies
(12) United States Patent (10) Patent No.: US 9,345,661 B2 Adler Et Al
Cyramza® (Ramucirumab)
EGFR and HER-2 Antagonists in Breast Cancer
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
Second-Line FOLFIRI Plus Ramucirumab with Or Without Prior
Anti-EGFR Antibody 528 Binds to Domain III of EGFR at a Site
Study Protocol C25002 Amendment 4, Eudract: 2011-001240-29
HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: an Antibody–Drug Conjugate for Breast Cancer
Necitumumab for First-Line Treatment of Advanced, Squamous, Non-Small-Cell Lung Cancer: a Relevant Step Forward?
Amivantamab: a Potent Novel EGFR/C-MET Bispecific Antibody Therapy for EGFR-Mutated Non-Small Cell Lung Cancer
The Current Landscape of Antibody-Based Therapies in Solid
288875133-Oa
Cetuximab Preclinical Antitumor Activity
Top View
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
View of This Manuscript
Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
ERBITUX (Cetuximab)
Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma
Development of HER2-Targeted Therapies for Gastrointestinal Cancer
Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-Cmet Bispecific Antibody, In
Combining Erlotinib and Cetuximab Is
Determining the Effects of Trastuzumab, Cetuximab and Afatinib By
Gastric Cancers
Strategies for Delaying Or Treating in Vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Jeanne M
Combination Therapy for EGFR-Mutant Lung Cancers
Erbitux, INN-Cetuximab
Assessment Report
Cetuximab Combined with Chemotherapy Is Beneficial for Patients with Advanced Non-Small Cell Lung Cancer After EGFR-Tyrosine Kinase Inhibitors Failure